Clinical Trials Logo

Carcinoma, Adenosquamous clinical trials

View clinical trials related to Carcinoma, Adenosquamous.

Filter by:
  • Completed  
  • Page 1 ·  Next »

NCT ID: NCT05337163 Completed - Lung Cancer Clinical Trials

A Multicenter Clinical Trial of Sputum DNA Testing for Lung Cancer in China

Start date: February 25, 2022
Phase:
Study type: Observational

The primary objective of this study is to assess the safety and effectiveness of Human Multigene Methylation Detection Kit (Fluorescent PCR Method) for help diagnose lung cancer by comparing with clinical standard method (includes chest CT examination or pathological examination).

NCT ID: NCT03215810 Completed - Clinical trials for Non-Small Cell Lung Cancer

Nivolumab and Tumor Infiltrating Lymphocytes (TIL) in Advanced Non-Small Cell Lung Cancer

Start date: October 11, 2017
Phase: Phase 1
Study type: Interventional

Investigators plan to study the safety, side effects, and benefits of tumor-infiltrating lymphocytes (TILs) when they are given with the drug nivolumab. Nivolumab is a type of immunotherapy - a drug that is used to boost the ability of the immune system to fight cancer, infection, and other diseases.

NCT ID: NCT02921269 Completed - Clinical trials for Cervical Adenocarcinoma

Atezolizumab and Bevacizumab in Treating Patients With Recurrent, Persistent, or Metastatic Cervical Cancer

Start date: March 10, 2017
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well atezolizumab and bevacizumab work in treating patients with cervical cancer that has come back, remains despite treatment, or has spread to other places in the body. Monoclonal antibodies, such as atezolizumab and bevacizumab, may shrink tumor cell and interfere with the ability of tumor cells to grow and spread.

NCT ID: NCT02394652 Completed - Clinical trials for Squamous Cell Carcinoma

The Potential for Metformin to Improve Tumor Oxygenation in Locally Advanced Cervix Cancer: A Phase II Randomized Trial

Start date: May 21, 2015
Phase: Phase 2
Study type: Interventional

Cervical cancer remains an important health problem worldwide. Poor tumor oxygenation (hypoxia) is associated with inferior survival in cervical cancer and resistance to radiation treatment. Hypoxia-modifying therapies improve survival, but existing therapies are impractical and/or toxic. Metformin, a non-toxic drug for diabetes, has been shown to decrease tumor hypoxia in animal studies and its use is associated with better survival in diabetic cancer patients. It is hypothesized that metformin may decrease cervical tumor hypoxia and thereby improve tumor response to radiation and survival in patients with locally advanced cervix cancer. This is a randomized, multicenter phase II study of standard chemoradiation in combination with metformin versus standard chemoradiation alone in women with locally advanced cervix cancer. Women randomized to the metformin group will take metformin starting 1 week prior to standard chemoradiation and throughout the duration of external radiation treatment. Tumor hypoxia will be measured by a special X-ray test called positron emission test (PET) performed with a hypoxia dye called FAZA. The main purpose of this study is to see if metformin decreases tumor hypoxia measured on FAZA-PET; information about response and side effects will also be collected.

NCT ID: NCT02164461 Completed - Clinical trials for Cervical Adenocarcinoma

Axalimogene Filolisbac (ADXS11-001) High Dose in Women With Human Papillomavirus (HPV) + Cervical Cancer

Start date: March 4, 2015
Phase: Phase 1
Study type: Interventional

To evaluate the tolerability and safety of axalimogene filolisbac 1 x 10^10 colony forming units (cfu) administered with prophylactic premedication in repeating 3-dose study cycles in women with persistent, metastatic, or recurrent squamous and non-squamous carcinoma, adenosquamous, or adenocarcinoma of the cervix. To evaluate tumor response and progression-free survival (PFS) by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 and immune-related Response Evaluation Criteria in Solid Tumors (irRECIST).

NCT ID: NCT01759355 Completed - Clinical trials for Cervical Squamous Cell Carcinoma

Hybrid PET/MR in the Therapy of Cervical Cancer

Start date: October 2012
Phase:
Study type: Observational

This is a two arm, single center feasibility study of 20 patients with non-metastatic cervical cancer managed with surgery and/or chemoradiation therapy at UNC Hospitals. Subjects will undergo PET/MRI scans before, during (chemoradiation group only), and after treatment.

NCT ID: NCT01711515 Completed - Clinical trials for Cervical Adenocarcinoma

Chemoradiation Therapy and Ipilimumab in Treating Patients With Stages IB2-IIB or IIIB-IVA Cervical Cancer

Start date: October 1, 2012
Phase: Phase 1
Study type: Interventional

This phase I trial studies the side effects and best dose of ipilimumab when given after chemoradiation therapy in treating patients with stages IB2-IIB or IIIB-IVA cervical cancer. Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high-energy x-rays to kill tumor cells and shrink tumors. Monoclonal antibodies, such as ipilimumab, may find tumor cells and help carry tumor-killing substances to them. Giving ipilimumab together with chemoradiation therapy may be a better way treat cervical cancer.

NCT ID: NCT01414608 Completed - Clinical trials for Cervical Adenocarcinoma

Cisplatin and Radiation Therapy With or Without Carboplatin and Paclitaxel in Patients With Locally Advanced Cervical Cancer

Start date: January 9, 2012
Phase: Phase 3
Study type: Interventional

This randomized phase III trial studies how well giving cisplatin and radiation therapy together with or without carboplatin and paclitaxel works in treating patients with cervical cancer has spread from where it started to nearby tissue or lymph nodes. Drugs used in chemotherapy, such as cisplatin, carboplatin, and paclitaxel, work in different ways to stop the growth of [cancer/tumor] cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. External radiation therapy uses high-energy x rays to kill tumor cells. Internal radiation uses radioactive material placed directly into or near a tumor to kill tumor cells. It is not yet known whether giving cisplatin and external and internal radiation therapy together with carboplatin and paclitaxel kills more tumor cells.

NCT ID: NCT01365156 Completed - Cervical Cancer Clinical Trials

Extraperitoneal Para-aortic Lymph Node Dissection (EPLND) for Cervix

Start date: August 2011
Phase: Phase 3
Study type: Interventional

The goal of this clinical research study is to learn if a surgical procedure called an extraperitoneal laparoscopic lymphadenectomy followed by chemotherapy and tailored radiation therapy can help to control the disease for a longer time than standard-of-care chemotherapy and whole pelvic radiation therapy.

NCT ID: NCT01307631 Completed - Clinical trials for Endometrial Adenocarcinoma

Akt Inhibitor MK2206 in Treating Patients With Recurrent or Advanced Endometrial Cancer

Start date: March 2011
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well Akt inhibitor MK2206 works in treating patients with recurrent or advanced endometrial cancer. Akt inhibitor MK2206 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.